
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 7 - Jul 12
For Your Every Summer RSVP, with Code: SUMMER15
Description
sFlt-1 Recombinant Rabbit mAb (SDT-233-26)Product Specification Host Rabbit Antigen sFlt 1 Synonyms Soluble Fms Like Tyrosine Kinase 1, sVEGFR 1 Immunogen Recombinant Protein Accession P17948 Clone Number SDT 233 26 Antibody Type Recombinant mAb Application CLIA, Sandwich ELISA Reactivity Hu Cross Reactivity Does not recognize PlGF Purification Protein A Concentration 2 mg ml Purity >95% by HPLC Conjugation Unconjugated Physical Appearance Liquid Storage Buffer PBS pH7. 4, 0. 03% Proclin 300
Product Specification
| Host | Rabbit |
| Antigen | sFlt-1 |
| Synonyms | Soluble Fms-Like Tyrosine Kinase-1, sVEGFR-1 |
| Immunogen | Recombinant Protein |
| Accession | P17948 |
| Clone Number | SDT-233-26 |
| Antibody Type | Recombinant mAb |
| Application | CLIA, Sandwich ELISA |
| Reactivity | Hu |
| Cross Reactivity | Does not recognize PlGF |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Purity | >95% by HPLC |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| Sandwich ELISA | N/A |
Background
Soluble fms-like tyrosine kinase-1 (sFlt-1 or sVEGFR-1) is a tyrosine kinase protein with antiangiogenic properties. A non-membrane associated splice variant of VEGF receptor 1 (Flt-1), sFlt-1 binds the angiogenic factors VEGF (vascular endothelial growth factor) and PlGF (placental growth factor), reducing blood vessel growth through reduction of free VEGF and PlGF concentrations. In humans, sFlt-1 is important in the regulation of blood vessel formation in diverse tissues, including the kidneys, cornea, and uterus. Abnormally high levels of sFlt-1 have been implicated in the pathogenesis of preeclampsia. Preeclampsia (PE) is a hypertensive pregnancy disorder that occurs in approximately 2% to 4% of all pregnancies and is accompanied by substantial morbidity and mortality for both mother and infant and long-term risks for chronic diseases. The exact causes of PE are still unclear, but contributors are systemic endothelial dysfunction, impaired angiogenesis, and decreased vascular compliance. In recent years, research has focused primarily on soluble anti-angiogenic factors, such as soluble fms-like tyrosine kinase-1 (sFlt-1) and pro-angiogenic factors, such as placental growth factor (PlGF). An anti-angiogenic imbalance upon increased sFlt-1 levels has been shown to be a critical factor in the pathogenesis of placentally associated disorders such as PE and is strongly associated with the crucial process of remodelling of the maternal spiral arteries. As an anti-angiogenic factor on the surface of vascular endothelial cells, sFlt-1 blocks the responses of the pro-angiogenic factors vascular endothelial growth factor (VEGF) and PlGF. Those changes in the concentration of angiogenic factors can be measured in maternal blood samples–an elevated sFlt-1/PlGF ratio can occur weeks before clinical symptoms of PE arise. Therefore, measurement of the sFlt-1/PlGF ratio has become an established marker in clinical practice for early prediction of PE.
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy